Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
about
Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewOptimizing bronchodilation in the prevention of COPD exacerbationsRecruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons Learned.
P2860
Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@ast
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@en
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@nl
type
label
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@ast
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@en
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@nl
prefLabel
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@ast
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@en
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@nl
P2093
P2860
P1433
P1476
Fluticasone propionate/salmete ...... ulmonary disease exacerbation.
@en
P2093
Amanda Emmett
Andrea N Morris
Ibrahim Raphiou
Jill A Ohar
Mark T Dransfield
Thomas J Ferro
P2860
P2888
P356
10.1186/S12931-014-0105-2
P577
2014-09-24T00:00:00Z
P5875
P6179
1052010594